Drug Trial Radar · NCT05944562
Tulmimetostat (DZR123) in Patients With Mycosis Fungoides and Sézary Syndrome
Last checked: Nov 20, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
24
Actual
Start
Jan 9, 2024
Primary completion
Feb 28, 2027
Study completion Jan 31, 2029
Sponsor
- Lead sponsor
- Washington University School of MedicineAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Novartis; The Foundation for Barnes-Jewish Hospital; Swim Across America; Daniel E. Corbin Jr. Lymphoma Fund
- First posted
- Jul 13, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The hypotheses of this study are that single agent DZR123 will be safe and well tolerated in patients with advanced (stage IB-IVB) mycosis fungoides (MF)/Sézary syndrome (SS) who have had at least one prior systemic therapy, and that in these patients, DZR123 will demonstrate efficacy and be worth of further study.
Conditions
- Mycosis Fungoides
- Sezary Syndrome
- Mycosis Fungoides/Sezary Syndrome
Interventions
TulmimetostatDrug
Patients should take DZR123 at approximately the same time every morning in a fasted state (no food for 2 hours prior and 1 hour following DZR123 dosing). Each dose of DZR123 should be taken with a glass of water and consumed over as short a time as possible.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency and grades of treatment-emergent adverse events (TEAE)Time frame: From start of treatment through 30 days after completion of treatment (estimated to be 13 months)
- Rate of treatment discontinuation due to treatment-emergent adverse events (TEAE)Time frame: From start of treatment through 30 days after completion of treatment (estimated to be 13 months)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Washington University School of Medicine
St Louis, Missouri
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.